Highlights

  • Genprex will present a TUSC2 gene therapy poster at the Gerontological Society of America meeting on 4 November 2026.
  • Meharry Medical College researchers published mouse data linking TUSC2 loss to hippocampal aging changes, especially in males.
  • Acclaim-3 targets enrollment of its first 25 small cell lung cancer patients by the end of 2026.
  • A Nasdaq Hearings Panel requires the closing bid price to stay at or above US$1.00 through 7 December 2026.

Genprex, Inc. (NASDAQ:GNPX) is exploring whether the tumor suppressor gene at the heart of its lead cancer therapy has relevance to aging, while its core lung cancer trials continue to enroll. The clinical-stage gene therapy company announced in October 2026 two research updates on TUSC2, the gene delivered by its investigational therapy REQORSA (quaratusugene ozeplasmid).

TUSC2 Research Moves Beyond Oncology

On 21 October 2026, Genprex highlighted a peer-reviewed mouse study by researchers at Meharry Medical College, published in Mechanisms of Ageing and Development. Loss of TUSC2 disrupted mitochondrial function, protein homeostasis and neuronal communication pathways in the hippocampus, with markedly stronger effects in males. An analysis of existing human datasets found that TUSC2 expression declined significantly with age in 11 of 13 brain regions. The study did not evaluate REQORSA for aging or neurodegenerative disease, and the company describes the findings as exploratory.

On 28 October, Genprex said Chief Medical Officer Mark Berger will present a poster titled TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program at the Gerontological Society of America 2026 meeting in National Harbor, Maryland, on 4 November 2026. The company noted that additional research is needed to determine whether the findings could support therapeutic development.

Lung Cancer and Diabetes Programs Advance

REQORSA is being tested in two Phase 1/2 trials. Acclaim-1 combines it with Tagrisso in EGFR-mutant non-small cell lung cancer, with the Phase 2a expansion enrolling. In August 2026, Genprex began a collaboration with Roche Diagnostics to validate TROP2-based biomarkers for patient selection, with validation expected around the end of 2026.

Acclaim-3 pairs REQORSA with Tecentriq as maintenance therapy in extensive-stage small cell lung cancer. Its Phase 2 expansion is enrolling about 50 patients, and the company expects to enroll the first 25 by the end of 2026, with an interim analysis planned for the first half of 2027. Both trials hold FDA Fast Track designation.

In diabetes, Genprex signed an agreement on 18 August with an unnamed US contract manufacturer to scale up production of its AAV-based gene therapy, which delivers the Pdx1 and MafA genes to the pancreas, as it works toward an investigational new drug filing.

Funding Runway and Listing Status

Genprex reported cash of US$15.2 million at 30 June 2026 and a Q2 2026 net loss of US$4.4 million. It expects cash to fund operations into the second half of 2027, although substantial doubt exists about its ability to continue as a going concern. During the first half, it raised about US$15.6 million in net proceeds through its at-the-market program.

The company completed a 1-for-22 Reverse Stock Split on 16 July 2026. On 4 August, a Nasdaq Hearings Panel confirmed that Genprex had regained compliance with the US$1.00 minimum bid price rule, subject to monitoring until 7 December 2026. Shares closed at US$2.24 on 30 October 2026, up 9.8% on the day, giving a market Capitalization of about US$1.84 million.